Martinelli, S <br/><br/>
Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils.  [electronic resource] 

 -  Oncogene  Nov 2006 
 - 6915-23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0950-9232 
<br/><br/><label>Standard No.: </label>10.1038/sj.onc.1209692  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3-Phosphoinositide-Dependent Protein Kinases<br/>Animals<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Apoptosis--drug effects<br/>Bone Marrow--drug effects<br/>Cells, Cultured<br/>Doxorubicin--adverse effects<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Immunoblotting<br/>Inhibitor of Apoptosis Proteins<br/>Lymphoma--drug therapy<br/>Mice<br/>Mice, Inbred C57BL<br/>Microtubule-Associated Proteins--drug effects<br/>Neoplasm Proteins--drug effects<br/>Neoplasms, Experimental--drug therapy<br/>Neutrophils--cytology<br/>Phosphatidylinositol 3-Kinases--drug effects<br/>Polymerase Chain Reaction<br/>Protein Serine-Threonine Kinases--drug effects<br/>Proto-Oncogene Proteins c-akt--drug effects<br/>Sirolimus--adverse effects<br/>Stem Cells--drug effects<br/>Survivin